Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate BioNTech SE before investing.

In this article, we go over a few key elements for understanding BioNTech SE’s stock price such as:

• BioNTech SE’s current stock price and volume
• Why BioNTech SE’s stock price changed recently
• Upgrades and downgrades for BNTX from analysts
• BNTX’s stock price momentum as measured by its relative strength

About BioNTech SE (BNTX)

Before we jump into BioNTech SE’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.

Want to learn more about BioNTech SE’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about BioNTech SE.

BioNTech SE’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, BioNTech SE’s stock price was $90.580.

BioNTech SE is down 2.44% from its previous closing price of $92.850.

During the last market session, BioNTech SE’s stock traded between $90.450 and $93.040. Currently, there are approximately 292.04 million shares outstanding for BioNTech SE.

BioNTech SE’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

BioNTech SE Stock Price History

BioNTech SE’s (BNTX) price is currently down 2.65% so far this month.

During the month of July, BioNTech SE’s stock price has reached a high of $98.810 and a low of $88.350.

Over the last year, BioNTech SE has hit prices as high as $124.000 and as low as $79.520. Year to date, BioNTech SE’s stock is down 4.85%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused BioNTech SE Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of July 30, 2026,, no analysts have changed their rating of BioNTech SE’s stock over the last month.

Additionally, you'll want to evaluate BioNTech SE’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on BioNTech SE’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

BioNTech SE’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about BioNTech SE (BNTX) by visiting AAII Stock Evaluator.

Relative Price Strength of BioNTech SE

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 30, 2026, BioNTech SE has a weighted four-quarter relative price strength of -8.46%, which translates to a Momentum Score of 26 and is considered to be Weak.

Want to learn more about how BioNTech SE is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

BioNTech SE Stock Price: Bottom Line

As of July 31, 2026, BioNTech SE’s stock price is $90.580, which is down 2.44% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like BioNTech SE stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.